, Volume 27, Issue 3, pp 275-279
Date: 03 Apr 2013

Dasatinib: A Guide to Its Use in Chronic Myeloid Leukemia in the EU

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Oral dasatinib (Sprycel®) is effective in the treatment of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) or imatinib-resistant or imatinib-intolerant chronic-phase, accelerated-phase, or blast-phase CML. In particular, dasatinib is associated with better and faster responses than imatinib in patients with newly diagnosed chronic-phase CML. The response to dasatinib appears to be maintained in the longer-term. Dasatinib has an acceptable tolerability profile; it is associated with myelosuppression, with fluid retention being the most common nonhematologic adverse event. Thus, dasatinib is a highly effective, once-daily therapy for the first-line treatment of patients with chronic-phase CML and for the second-line treatment of imatinib-resistant or imatinib-intolerant CML.

The manuscript was reviewed by: S. Mustjoki, Hematology Research Unit, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland; G. Saglio, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.